A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

AIM: In this study, efficacy, tolerability and safety of biosimilar adalimumab (Exemptia; Zydus Cadila) was compared with reference adalimumab (Humira; AbbVie) in patients with moderate to severe rheumatoid arthritis (RA). METHOD: In this multicentre, prospective, randomized, double‐blind, active co...

Descripción completa

Detalles Bibliográficos
Autores principales: Jani, Rajendrakumar H., Gupta, Rajiv, Bhatia, Girish, Rathi, Gaurav, Ashok Kumar, Patnala, Sharma, Reena, Kumar, Uma, Gauri, Liyakat A., Jadhav, Praveen, Bartakke, Girishchandra, Haridas, Vikram, Jain, Dinesh, Mendiratta, Sanjeev K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215647/
https://www.ncbi.nlm.nih.gov/pubmed/26176644
http://dx.doi.org/10.1111/1756-185X.12711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215647/
https://www.ncbi.nlm.nih.gov/pubmed/26176644
http://dx.doi.org/10.1111/1756-185X.12711

Ejemplares similares